Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,251,079
  • Shares Outstanding, K 771,150
  • Annual Sales, $ 0 K
  • Annual Income, $ -221,320 K
  • EBIT $ -935 M
  • EBITDA $ -935 M
  • 60-Month Beta -1.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 56.39

Options Overview Details

View History
  • Implied Volatility 101.16% (+17.91%)
  • Historical Volatility 63.84%
  • IV Percentile 52%
  • IV Rank 34.71%
  • IV High 183.25% on 01/27/26
  • IV Low 57.51% on 01/21/26
  • Expected Move (DTE 2) 1.02 (7.08%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 397
  • Volume Avg (30-Day) 3,316
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 55,721
  • Open Int (30-Day) 72,329
  • Expected Range 13.39 to 15.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.17
  • Low Estimate -0.32
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -212.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.03 +2.92%
on 02/02/26
20.20 -28.51%
on 01/09/26
-3.08 (-17.58%)
since 01/02/26
3-Month
14.03 +2.92%
on 02/02/26
20.20 -28.51%
on 01/09/26
-3.05 (-17.44%)
since 11/04/25
52-Week
14.03 +2.92%
on 02/02/26
36.91 -60.88%
on 04/24/25
-6.18 (-29.97%)
since 02/04/25

Most Recent Stories

More News
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 257,368 shares of common stock....

SMMT : 14.31 (-1.92%)
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

BLA Filing Based on HARMONi Global Phase III Study Results PDUFA Goal Action Date of November 14, 2026 Significant Unmet Need Remains;...

SMMT : 14.31 (-1.92%)
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)

Summit to Advance Development Opportunities of Ivonescimab with GSK’s Novel B7-H3 risvutatug rezetecan Multiple Solid Tumor Settings to Be Pursued with Clinical Trials...

SMMT : 14.31 (-1.92%)
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Significant Unmet Need Remains in this Setting Over 14,000 Patients are Eligible for 2L+ Treatment in This Setting in the United States Each Year ...

SMMT : 14.31 (-1.92%)
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock....

SMMT : 14.31 (-1.92%)
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 44 th Annual J.P. Morgan Healthcare...

SMMT : 14.31 (-1.92%)
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock....

SMMT : 14.31 (-1.92%)
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing Regimen Ivonescimab Plus...

SMMT : 14.31 (-1.92%)
Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferences during the remainder...

SMMT : 14.31 (-1.92%)
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen

SMMT : 14.31 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 15.50
2nd Resistance Point 15.13
1st Resistance Point 14.86
Last Price 14.31
1st Support Level 14.22
2nd Support Level 13.86
3rd Support Level 13.59

See More

52-Week High 36.91
Fibonacci 61.8% 28.17
Fibonacci 50% 25.47
Fibonacci 38.2% 22.77
Last Price 14.31
52-Week Low 14.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar